Cryoport Provides Positive Update on MVE Biological Solution’s New Prague Facility

Production is expected to resume the week of February 14, 2022

NASHVILLE, Tenn., February 9, 2022 /PRNewswire/ — Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, has provided today an update on the resumption of activities at the New Prague facility. As previously announced, a fire broke out in part of the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota on January 25, 2022, leading to a temporary reduction in production. the New Prague manufactures aluminum dewars and is one of three global manufacturing facilities for MVE Biological Solutions.

Cryoport, Inc.

Cryoport plans to resume production at New Prague installation during the week of February 14thand and ramping up to full production during the first quarter of 2022. The Company anticipates the revenue impact of $4 for $5 million limited to the first trimester. In addition, the Company expects its insurance to cover the majority of the costs of restoring and reopening the facility, as well as losses related to business interruption.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), headquartered in Nashville, TN, is a global leader in temperature-controlled supply chain solutions for the life sciences industry, supporting lifesaving cell and gene therapies across the clinical and commercial spectrum. With 33 strategic locations spanning the Americas, EMEA (Europethe Middle East and Africa) and APAC (Asia Pacific), Cryoport’s global platform provides critical solutions, services and products to biopharma, animal health and reproductive medicine customers worldwide. In addition to its industry-leading supply chain solutions, Cryoport is the world’s largest manufacturer of cryogenic systems and one of the largest life science-focused specialty couriers. From September 30, 2021Cryoport has supported eight commercial cell and gene therapies and 582 regenerative medicine clinical trials worldwide, including 70 in phase 3.

For more information, visit or follow @cryoport on Twitter at for live updates.

Forward-looking statements
Statements in this press release that are not purely historical, including statements regarding the Company’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions, are statements forward-looking statements within the meaning of the Private Securities Litigation Reform Act. of 1995. Such forward-looking statements include, but are not limited to, those relating to the industry, business, plans, strategy, acquisitions, including CRYOPDP and MVE Biological Solutions, financial results and condition financial of the Company. It is important to note that the actual results of the Company could differ materially from those of these forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, product market trends, cash flow variations of the Company, market acceptance risks and technical development risks. . The Company’s business could be affected by a number of other factors, including the risk factors discussed in the Company’s Securities and Exchange Commission (“SEC”) reports, including, but not limit, the Company’s annual report on Form 10-K for the three and twelve months ended December 31, 2020 and any subsequent SEC filings. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on such forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements contained in this press release.



Show original content to download multimedia:

SOURCE Cryoport, Inc.

Comments are closed.